424 related articles for article (PubMed ID: 32269728)
1. Immunotherapy in anaplastic thyroid cancer.
Ma M; Lin B; Wang M; Liang X; Su L; Okose O; Lv W; Li J
Am J Transl Res; 2020; 12(3):974-988. PubMed ID: 32269728
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma?
Gao X; Hong C; Xie Y; Zeng X
Front Oncol; 2023; 13():1103147. PubMed ID: 37007127
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for anaplastic thyroid carcinoma: the present and future.
Lu X; Bao L; Pan Z; Ge M
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2021 Dec; 50(6):675-684. PubMed ID: 35347912
[TBL] [Abstract][Full Text] [Related]
4. Research progress of immunotherapy against anaplastic thyroid cancer.
Chen J; Xiao Z; Wu H
Front Oncol; 2024; 14():1365055. PubMed ID: 38595813
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in breast cancer: An overview of modern checkpoint blockade strategies and vaccines.
Sanchez K; Page D; McArthur HL
Curr Probl Cancer; 2016; 40(2-4):151-162. PubMed ID: 27855963
[TBL] [Abstract][Full Text] [Related]
6. TIM3 Expression in Anaplastic-Thyroid-Cancer-Infiltrating Macrophages: An Emerging Immunotherapeutic Target.
Palacios LM; Peyret V; Viano ME; Geysels RC; Chocobar YA; Volpini X; Pellizas CG; Nicola JP; Motran CC; Rodriguez-Galan MC; Fozzatti L
Biology (Basel); 2022 Nov; 11(11):. PubMed ID: 36358310
[TBL] [Abstract][Full Text] [Related]
7. Harnessing Immunity to Treat Advanced Thyroid Cancer.
Komatsuda H; Kono M; Wakisaka R; Sato R; Inoue T; Kumai T; Takahara M
Vaccines (Basel); 2023 Dec; 12(1):. PubMed ID: 38250858
[TBL] [Abstract][Full Text] [Related]
8. Human anaplastic thyroid carcinoma cells are sensitive to NK cell-mediated lysis via ULBP2/5/6 and chemoattract NK cells.
Wennerberg E; Pfefferle A; Ekblad L; Yoshimoto Y; Kremer V; Kaminskyy VO; Juhlin CC; Höög A; Bodin I; Svjatoha V; Larsson C; Zedenius J; Wennerberg J; Lundqvist A
Clin Cancer Res; 2014 Nov; 20(22):5733-44. PubMed ID: 25212604
[TBL] [Abstract][Full Text] [Related]
9. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
[TBL] [Abstract][Full Text] [Related]
10. Current and future of immunotherapy for thyroid cancer based on bibliometrics and clinical trials.
Wang K; Zhang Y; Xing Y; Wang H; He M; Guo R
Discov Oncol; 2024 Feb; 15(1):50. PubMed ID: 38403820
[TBL] [Abstract][Full Text] [Related]
11. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells.
Jiang K; Song C; Kong L; Hu L; Lin G; Ye T; Yao G; Wang Y; Chen H; Cheng W; Barr MP; Liu Q; Zhang G; Ding C; Meng S
BMC Cancer; 2018 Jul; 18(1):746. PubMed ID: 30021550
[TBL] [Abstract][Full Text] [Related]
12. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
13. The control of anaplastic thyroid carcinoma cell lines by oncolytic poxviruses.
Mundi N; Um S; Yoo J; Rizzo G; Black M; Pinto N; Palma DA; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
Virus Res; 2014 Sep; 190():53-9. PubMed ID: 25038405
[TBL] [Abstract][Full Text] [Related]
14. Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer.
Cantara S; Bertelli E; Occhini R; Regoli M; Brilli L; Pacini F; Castagna MG; Toti P
Endocrine; 2019 Apr; 64(1):122-129. PubMed ID: 30762153
[TBL] [Abstract][Full Text] [Related]
15. Thyroid dysfunctions secondary to cancer immunotherapy.
Chalan P; Di Dalmazi G; Pani F; De Remigis A; Corsello A; Caturegli P
J Endocrinol Invest; 2018 Jun; 41(6):625-638. PubMed ID: 29238906
[TBL] [Abstract][Full Text] [Related]
16. Targeting lipid metabolism for the treatment of anaplastic thyroid carcinoma.
von Roemeling CA; Copland JA
Expert Opin Ther Targets; 2016; 20(2):159-66. PubMed ID: 26414044
[TBL] [Abstract][Full Text] [Related]
17. Novel treatments for anaplastic thyroid carcinoma.
Ferrari SM; Elia G; Ragusa F; Ruffilli I; La Motta C; Paparo SR; Patrizio A; Vita R; Benvenga S; Materazzi G; Fallahi P; Antonelli A
Gland Surg; 2020 Jan; 9(Suppl 1):S28-S42. PubMed ID: 32055496
[TBL] [Abstract][Full Text] [Related]
18. Anaplastic thyroid cancer: prevalence, diagnosis and treatment.
Chiacchio S; Lorenzoni A; Boni G; Rubello D; Elisei R; Mariani G
Minerva Endocrinol; 2008 Dec; 33(4):341-57. PubMed ID: 18923370
[TBL] [Abstract][Full Text] [Related]
19. Virotherapy as a Potential Therapeutic Approach for the Treatment of Aggressive Thyroid Cancer.
Malfitano AM; Somma SD; Prevete N; Portella G
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31636245
[TBL] [Abstract][Full Text] [Related]
20. Review Article: Immune Landscape and Immunotherapy Options in Cervical Carcinoma.
Kousar K; Ahmad T; Naseer F; Kakar S; Anjum S
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
